secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016063
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology appoints Jitendra Wadhane as Chief Accounting Officer
--------------------------------------------------------------------

- Mr. Wadhane appointed CAO and Principal Accounting Officer effective August 3, 2022.
- He previously served as SVP of Finance and Corporate Controller since August 2021.
- Prior roles include Head of SEC Reporting at Immunovant and Senior Manager at EY.
- He is a CPA with a Bachelor's from University of Mumbai and Chartered Accountancy from ICAI.
- No family relationships or arrangements with other directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022016063/0000950170-22-016063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022016063/pyxs-20220803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer